Last Update 01 Apr 26

Fair value Increased 163%

BFLY: Embedded Ultrasound Platform Is Expected To Reshape Future Earnings Profile

Analysts have increased the price target for Butterfly Network from $2.00 to $5.25, reflecting updated assumptions around revenue growth, profit margins, and future P/E. Recent research points to stronger contribution from Butterfly Embedded alongside the core POCUS business.

Analyst Commentary

Street research has highlighted Butterfly Embedded as an increasingly important driver alongside the core point of care ultrasound, or POCUS, business, with some firms updating their price targets to reflect this mix. One major firm, for example, referenced stronger Q4 results and described Butterfly Embedded as becoming a bigger part of the story as it adds a new revenue stream and tilts the profile more toward technology than traditional med tech.

For you as an investor, the key takeaway is that recent research commentary is not just reacting to near term results. It is also recalibrating expectations for how much Butterfly Embedded could matter relative to the legacy POCUS offering. That kind of shift can influence how analysts think about valuation frameworks, revenue durability, and the potential role of software and platform economics over time.

At the same time, not all commentary is purely constructive, and some research focuses on what still needs to go right for the thesis to play out.

Bearish Takeaways

Bearish analysts point to execution risk around scaling Butterfly Embedded and caution that any delays in adoption or integration could limit how much this segment contributes to revenue and margins versus current expectations.
Some caution centers on valuation risk, with concerns that the stock price may already reflect optimistic assumptions about both POCUS and Butterfly Embedded growth, leaving less room for error if customer uptake or deal timing is uneven.
Bearish analysts also highlight the challenge of balancing investment in new technology with the path toward improved profitability and warn that higher spending on R&D and commercialization could weigh on earnings if revenue does not ramp as modeled.
There are concerns that competition in both ultrasound hardware and software could pressure pricing and limit future P/E expansion, especially if Butterfly Embedded does not clearly differentiate itself in real world clinical and enterprise workflows.

What's in the News

Butterfly received U.S. FDA clearance for a fully automated Gestational Age Tool integrated into its handheld ultrasound solution, described as the first FDA cleared blind sweep AI tool for estimating gestational age, aimed at improving maternal and fetal care, including in low resource settings (Key Developments).
The Gestational Age Tool is trained on more than 21 million images across diverse demographics and care settings and is designed to deliver gestational age estimates in under two minutes via an automated three step process, with deployment already underway in countries such as Malawi and Uganda, supported in part by a Gates Foundation grant (Key Developments).
Butterfly announced that its Butterfly iQ+/iQ3 and Compass AI ultrasound solution achieved GovRAMP and TX RAMP authorizations, enabling the company to sell cloud services to U.S. state and local government agencies, including Texas, under standardized security and compliance frameworks (Key Developments).
The company provided earnings guidance for fiscal 2026, indicating expected revenue of US$117 million to US$121 million, and separate revenue guidance for the fourth quarter of 2025 that points to at least 17% year over year growth (Key Developments).
Butterfly plans to release a Beam Steering API in the first half of 2026 to support advanced third party AI applications via its Butterfly Garden and Ultrasound on Chip co development programs, with planned SDK access across presets such as abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging, subject to development, regulatory, and partner factors (Key Developments).

Valuation Changes

Fair Value: Updated from $2.00 to $5.25, implying a higher assessed value per share based on the latest assumptions.
Discount Rate: Adjusted slightly from 7.58% to 7.70%, a modest change in the required rate of return used in the model.
Revenue Growth: Assumption moved from 14.04% to 16.70%, reflecting a higher modeled top line growth rate for the business.
Net Profit Margin: Margin input shifted from 12.49% to 13.08%, indicating a slightly higher expected level of profitability in the forecasts.
Future P/E: Target P/E multiple increased from 47.32x to 89.52x, a higher valuation multiple applied to projected earnings.

1 view

Key Takeaways

Delays in closing key enterprise deals, provider hesitancy, and global funding uncertainty may hinder Butterfly Network's revenue growth and widespread adoption.
High R&D spending and market commoditization risks could limit margin expansion and delay sustainable profitability despite growing commercial interest and an expanding platform ecosystem.
Prolonged sales cycles, shrinking high-margin software revenue, persistent cash burn, and rising churn threaten profitability and future growth, heightening risk of further shareholder dilution.

Catalysts

About Butterfly Network

Develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Although Butterfly Network is strongly positioned to benefit from the expansion of digital health and telemedicine, ongoing delays in closing large enterprise and global health deals reveal vulnerability to external policy decisions and constrained healthcare budgets, potentially limiting revenue growth in the near-to-intermediate term.
While the company's cloud-based AI software and upcoming Compass AI platform are set to drive enterprise adoption and increase high-margin recurring revenues, persistent churn in individual software subscriptions and slower-than-expected conversion from product to SaaS revenue could weigh on net margin improvements.
Despite successful pilots and growing commercial traction with HomeCare and AI-powered diagnostic tools, widespread adoption may be hampered by healthcare provider hesitancy, prolonged procurement cycles, and continued uncertainty in global health funding, which could suppress the top-line ramp for both product and services.
Even as Butterfly leverages long-term advances in miniaturization and cost reduction for portable diagnostics, the threat of increasing commoditization and availability of lower-cost overseas alternatives may pressure average selling prices, restricting gross margin expansion over the long run.
Although the platform ecosystem with Butterfly Garden and third-party AI apps expands the company's addressable market and could enhance customer lock-in, ongoing high R&D and investment requirements to stay technologically relevant will burden profitability and extend the timeline for achieving consistent positive earnings.

Butterfly Network Earnings and Revenue Growth

Butterfly Network Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Butterfly Network compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Butterfly Network's revenue will grow by 16.7% annually over the next 3 years.
The bearish analysts are not forecasting that Butterfly Network will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Butterfly Network's profit margin will increase from -79.0% to the average US Medical Equipment industry of 13.1% in 3 years.
If Butterfly Network's profit margin were to converge on the industry average, you could expect earnings to reach $20.3 million (and earnings per share of $0.07) by about April 2029, up from -$77.1 million today.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 89.8x on those 2029 earnings, up from -13.3x today. This future PE is greater than the current PE for the US Medical Equipment industry at 27.5x.
The bearish analysts expect the number of shares outstanding to grow by 2.97% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.7%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Ongoing macroeconomic uncertainty and healthcare funding reductions, both in the US and internationally, are causing delays or reductions in purchasing decisions for new medical devices, which risks prolonging slow revenue growth and flattening top-line gains.
Large enterprise and medical school deals have not closed as quickly as anticipated, and the sales cycle remains long and unpredictable, reducing near-term visibility and increasing the risk of missing revenue targets over the next several quarters.
The company's software and other services revenue mix has shrunk relative to hardware, and recurring ARR growth remains modest, which could slow the shift to higher-margin, predictable revenue streams and dampen overall gross margin expansion.
Butterfly Network has experienced persistent cash burn, reporting an adjusted EBITDA loss and using $46 million in cash over the trailing 12 months; if expense reductions or new high-margin revenue streams do not materialize soon, future dilutive capital raises could negatively impact earnings per share.
Individual software subscription churn remains a headwind, so without improved product stickiness and better renewal rates, SaaS revenues could stagnate or decline, putting pressure on gross margin and net income growth despite enterprise gains.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Butterfly Network is $5.25, which represents up to two standard deviations below the consensus price target of $5.56. This valuation is based on what can be assumed as the expectations of Butterfly Network's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $5.25.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $155.1 million, earnings will come to $20.3 million, and it would be trading on a PE ratio of 89.8x, assuming you use a discount rate of 7.7%.
Given the current share price of $4.04, the analyst price target of $5.25 is 23.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Butterfly Network?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Delays And Burn Will Hinder Progress While Telehealth Will Help